Health Trials

About this trial

The goal of this research study is to learn whether investigators can successfully give the PediRISE program to families-in other words, whether most families are interested in participating in a study about the PediRISE program, including a 50-50 chance of receiving standard usual care, and a 50-50 chance of receiving the PediRISE support program.

The names of the study groups in this research study are:

* PediRISE Program Group * Usual Care Group

Eligibility criteria

Qualifiers

Child diagnosed with de novo cancer

Child has established care at a study site and initiated cancer directed therapy in the prior 2-months

Child planned to receive at least 4-months of cancer-directed therapy at study site from time of diagnosis per initial cancer treatment plan

Child is <18 years at time of enrollment

Disqualifiers

Planned transfer of child to a non-DFCI or non-Columbia facility for cancer-directed therapy

Foreign national family receiving care as an Embassy-pay patient

Child is enrolled on embedded correlative health equity aims of open or upcoming clinical drug trials which are powered on descriptive parent-reported poverty data (e.g. AALL1731, DFCI 25-001). Co-enrollment on a poverty intervention study would confound the specified endpoints of these open trial correlative studies

Child or household member receiving SSI

Trial design

Treatments tested in this trial

  • PediRISE Resource Program

Treatment groups

40 Participants
are divided into 2 treatment groups

Locations

4
University of California San Francisco94143, San FranciscoCalifornia, United States
Boston Children's Hospital02215, BostonMassachusetts, United States
Dana Farber Cancer Institute02215, BostonMassachusetts, United States
Columbia University Medical Center10032, New YorkNew York, United States

Sponsors and collaborators

Dana-Farber Cancer Institute

Lead sponsor

American Cancer Society, Inc.

Collaborator

Children's Cancer Research Fund

Collaborator

Source ClinicalTrials.gov